Home » Clarification

Clarification

Dec 19, 2003
Premium

In last week’s RNAinsider feature, RNAi News listed Novartis’ William Wishart’s position as “head of functional genomics/chronic pain project.” RNAi News wishes to make clear that Wishart is head of the functional genomics’ chronic pain project, not head of the company’s functional genomics operations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

DNA Testing for Reunification Raises Ethics Issues

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

To Make Sure

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

Database of Trees

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

This Week in PLOS

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.

Jul
19
Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.